



MEN

FIRST CANCER SITE  
**MYELOMA**MYELOMA  
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

MIELOMA  
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
<b>SECOND CANCER SITE</b>			<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>O</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>		
<b>ALL SITES, BUT SKIN AND MYELOMA</b>	620	<b>31536</b>	620	<b>0.92</b>	792	<b>1.12</b>	172	<b>4.63</b>	135	0.92	301	<b>0.84</b>	137	1.03	47	<b>1.43</b>	-1.68	<b>2.46</b>
HEAD AND NECK	28		28	1.05	33	1.17	5	<b>3.30</b>	5	0.82	12	0.82	8	1.59	3	2.72	0.04	0.14
ORAL CAVITY	9		9	1.44	10	1.51	1	2.85	2	1.42	4	1.18	1	0.84	2	7.43	0.09	0.10
PHARYNX	8		8	1.44	8	1.36	0	0.00	2	1.59	2	0.66	3	2.86	1	4.46	0.08	0.06
LARYNX	11		11	0.74	15	0.95	4	<b>4.66</b>	1	0.29	6	0.74	4	1.44	0	0.00	-0.13	-0.02
OESOPHAGUS	11		11	1.56	12	1.61	1	2.50	2	1.26	6	1.58	2	1.48	1	3.19	0.13	0.14
STOMACH	37		37	0.88	40	0.90	3	1.21	6	0.62	19	0.85	9	1.11	3	1.53	-0.16	-0.14
COLON RECTUM	80		80	0.86	102	1.03	22	<b>4.30</b>	14	0.69	45	0.91	17	0.91	4	0.85	-0.43	0.10
COLON	54		54	0.84	76	1.12	22	<b>6.31</b>	9	0.65	33	0.97	9	0.69	3	0.90	-0.32	0.25
RECTUM	26		26	0.89	26	0.84	0	0.00	5	0.77	12	0.77	8	1.39	1	0.71	-0.10	-0.15
LIVER	31		31	1.14	41	<b>1.43</b>	10	<b>6.67</b>	11	1.84	13	0.89	6	1.13	1	0.78	0.12	0.37
GALLBLADDER	7		7	0.94	9	1.14	2	4.75	3	1.82	3	0.76	1	0.68	0	0.00	-0.01	0.03
PANCREAS	19		19	1.03	19	0.97	0	0.00	7	1.74	7	0.71	3	0.81	2	2.12	0.02	-0.02
LUNG	121		121	1.02	163	<b>1.30</b>	42	<b>6.29</b>	27	1.02	61	0.96	24	1.05	9	1.65	0.08	<b>1.14</b>
SKIN MELANOMA	9		9	0.99	11	1.15	2	4.29	2	1.06	4	0.83	2	1.06	1	2.10	0.00	0.04
MESOTHELIOMA	6		6	1.72	9	<b>2.46</b>	3	<b>16.52</b>	4	<b>5.44</b>	1	0.54	0	0.00	1	5.65	0.08	0.16
KAPOSI SARCOMA	4		4	2.75	6	<b>3.91</b>	2	<b>24.09</b>	1	3.06	3	3.86	0	0.00	0	0.00	0.08	0.13
SOFT TISSUE	2		2	0.87	2	0.82	0	0.00	1	1.99	1	0.81	0	0.00	0	0.00	-0.01	-0.01
BONE	0		0	0.00	1	1.58	1	28.53	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	0.01
BREAST	2		2	1.39	2	1.31	0	0.00	1	3.18	0	0.00	1	3.49	0	0.00	0.02	0.01
PROSTATE	106		106	<b>0.79</b>	143	1.01	37	<b>5.22</b>	22	0.78	52	<b>0.73</b>	22	0.79	10	1.44	-0.91	0.04
TESTIS	0		0	0.00	1	1.39	1	26.37	0	0.00	0	0.00	0	0.00	0	0.00	-0.02	0.01
KIDNEY AND RENAL PELVIS	24		24	1.17	40	<b>1.85</b>	16	<b>14.54</b>	4	0.90	10	0.91	8	1.94	2	1.99	0.11	<b>0.55</b>
BLADDER AND URINARY TRACT	74		74	0.97	89	1.11	15	<b>3.54</b>	14	0.84	35	0.86	22	1.47	3	0.81	-0.06	0.26
URINARY BLADDER	73		73	1.00	88	1.15	15	<b>3.71</b>	14	0.87	35	0.90	21	1.47	3	0.85	0.01	0.34
URINARY TRACT	1		1	0.30	1	0.29	0	0.00	0	0.00	0	0.00	1	1.51	0	0.00	-0.07	-0.08
BRAIN AND CENTRAL NERVOUS SYSTEM	11		11	1.47	11	1.40	0	0.00	3	1.82	5	1.24	2	1.38	1	2.93	0.11	0.09
THYROID	2		2	0.70	4	1.33	2	<b>13.61</b>	0	0.00	2	1.30	0	0.00	0	0.00	-0.03	0.03
HODGKIN LYMPHOMA	4		4	3.18	4	3.01	0	0.00	1	3.50	0	0.00	1	4.22	2	<b>37.72</b>	0.09	0.08
NON-HODGKIN LYMPHOMA	5		5	<b>0.27</b>	6	<b>0.30</b>	1	0.98	0	<b>0.00</b>	3	<b>0.30</b>	1	0.27	1	1.09	<b>-0.44</b>	<b>-0.42</b>
MYELOMA	0		0	<b>0.00</b>	0	<b>0.00</b>	0	0.00	0	0.00	0	<b>0.00</b>	0	0.00	0	0.00	<b>-0.29</b>	<b>-0.29</b>
LEUKAEMIAS	13		13	0.83	13	0.78	0	0.00	1	0.28	8	0.96	1	0.32	3	3.93	-0.09	-0.11
LYMPHOID LEUKAEMIAS	1		1	<b>0.13</b>	1	<b>0.13</b>	0	0.00	0	0.00	1	0.25	0	0.00	0	0.00	<b>-0.21</b>	<b>-0.21</b>
MYELOID LEUKAEMIAS	10		10	1.42	10	1.34	0	0.00	1	0.64	7	1.87	1	0.72	1	2.83	0.09	0.08
OTHER LEUKAEMIAS	2		2	1.73	2	1.63	0	0.00	0	0.00	0	0.00	0	0.00	2	<b>36.39</b>	0.03	0.02
OTHER AND ILL DEFINED SITES	24		24	<b>0.67</b>	31	0.82	7	<b>3.48</b>	6	0.76	11	0.58	7	0.98	0	0.00	-0.37	-0.20

Decrease/Difetto  
Increase/Eccesso

O Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE  
**MYELOMA**MYELOMA  
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

MIELOMA  
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
<b>SECOND CANCER SITE</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>0</b>	<b>SIR</b>	<b>EAR</b>	<b>EAR</b>
ALL SITES, BUT SKIN AND MYELOMA	402	1.00	483	1.15	81	3.79	76	0.89	218	1.03	82	1.03	26	1.09	0.05	1.74
HEAD AND NECK	8	1.57	8	1.49	0	0.00	1	0.93	5	1.86	2	1.97	0	0.00	0.09	0.07
ORAL CAVITY	4	1.43	4	1.36	0	0.00	1	1.71	2	1.37	1	1.78	0	0.00	0.04	0.03
PHARYNX	1	0.93	1	0.89	0	0.00	0	0.00	0	0.00	1	4.74	0	0.00	0.00	0.00
LARYNX	3	2.43	3	2.31	0	0.00	0	0.00	3	4.58	0	0.00	0	0.00	0.05	0.05
OESOPHAGUS	0	0.00	1	0.46	1	8.94	0	0.00	0	0.00	0	0.00	0	0.00	-0.06	-0.03
STOMACH	32	1.26	33	1.23	1	0.69	5	0.89	20	1.49	5	1.03	2	1.40	0.20	0.17
COLON RECTUM	61	0.94	82	1.20	21	6.03	16	1.16	33	0.97	12	0.93	0	0.00	-0.11	0.39
COLON	48	1.03	62	1.27	14	5.61	14	1.41	26	1.06	8	0.86	0	0.00	0.05	0.37
RECTUM	13	0.72	20	1.05	7	7.11	2	0.51	7	0.73	4	1.12	0	0.00	-0.15	0.03
LIVER	17	1.48	19	1.56	2	3.19	0	0.00	9	1.48	5	2.20	3	4.39	0.16	0.19
GALLBLADDER	7	0.76	7	0.72	0	0.00	1	0.49	6	1.23	0	0.00	0	0.00	-0.07	-0.08
PANCREAS	28	1.65	29	1.62	1	1.10	9	2.51	13	1.47	3	0.87	3	2.72	0.33	0.31
LUNG	29	1.12	39	1.43	10	7.47	5	0.93	16	1.18	7	1.33	1	0.60	0.09	0.33
SKIN MELANOMA	12	1.73	14	1.93	2	5.67	1	0.70	10	2.74	1	0.71	0	0.00	0.15	0.19
MESOTHELIOMA	2	1.87	2	1.78	0	0.00	0	0.00	2	3.57	0	0.00	0	0.00	0.03	0.02
KAPOSI SARCOMA	1	1.71	2	3.25	1	30.62	0	0.00	1	3.26	0	0.00	0	0.00	0.01	0.04
SOFT TISSUE	0	0.00	1	0.58	1	11.56	0	0.00	0	0.00	0	0.00	0	0.00	-0.05	-0.02
BONE	1	2.21	2	4.18	1	40.06	0	0.00	0	0.00	1	11.44	0	0.00	0.02	0.04
BREAST	76	0.77	94	0.91	18	3.52	8	0.38	41	0.79	19	0.97	8	1.42	-0.66	-0.26
CERVIX UTERI	2	0.40	4	0.75	2	7.09	0	0.00	1	0.37	0	0.00	1	4.07	-0.09	-0.04
CORPUS UTERI	15	0.83	18	0.94	3	3.15	4	1.03	8	0.83	2	0.56	1	1.00	-0.09	-0.03
OVARY	25	2.01	27	2.06	2	3.00	8	2.98	8	1.21	7	2.86	2	2.84	0.37	0.39
KIDNEY AND RENAL PELVIS	14	1.43	21	2.04	7	13.84	5	2.45	4	0.78	4	2.02	1	1.64	0.13	0.30
BLADDER AND URINARY TRACT	18	1.13	23	1.37	5	5.86	2	0.59	11	1.32	4	1.26	1	1.02	0.06	0.18
URINARY BLADDER	16	1.08	21	1.35	5	6.31	1	0.32	10	1.29	4	1.35	1	1.10	0.04	0.15
URINARY TRACT	2	1.77	2	1.68	0	0.00	1	4.19	1	1.69	0	0.00	0	0.00	0.03	0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	7	1.20	7	1.14	0	0.00	4	3.21	3	0.97	0	0.00	0	0.00	0.03	0.02
THYROID	5	0.79	6	0.91	1	3.23	3	2.33	2	0.60	0	0.00	0	0.00	-0.04	-0.02
HODGKIN LYMPHOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
NON-HODGKIN LYMPHOMA	2	0.13	2	0.13	0	0.00	0	0.00	1	0.12	1	0.33	0	0.00	-0.39	-0.40
MYELOMA	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.22	-0.22
LEUKAEMIAS	17	1.64	17	1.56	0	0.00	1	0.45	10	1.83	4	1.96	2	3.31	0.20	0.17
LYMPHOID LEUKAEMIAS	1	0.22	1	0.20	0	0.00	0	0.00	0	0.00	1	1.12	0	0.00	-0.11	-0.11
MYELOID LEUKAEMIAS	16	3.31	16	3.15	0	0.00	1	0.97	10	3.94	3	3.10	2	6.77	0.33	0.31
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.03	-0.03
OTHER AND ILL DEFINED SITES	23	0.74	25	0.77	2	1.18	3	0.45	14	0.86	5	0.81	1	0.52	-0.24	-0.22

Decrease/Difetto  
Increase/Eccesso

Observed cases  
Casi osservati

SIR Standardized Incidence Ratio  
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk  
Eccesso assoluto di rischio